Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients

Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients
Rubraca (rucaparib) maintenance treatment significantly improved survival without further disease progression among ovarian cancer patients taking part in a Phase 3 clinical trial, researchers showed in a presentation at the ongoing European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. The treatment benefitted patients with different types of genetic flaws that impact their ability to repair damaged DNA. Clovis Oncology — Rubraca’s developer — now aims to use the data to expand the drug’s regulatory approval to also include second line or later maintenance treatment, in addition to its approved use as a single therapy for ovarian cancer patients with mutations in their BRCA genes, who have received earlier chemotherapy treatment. “These results reinforce rucaparib’s potential to provide an enduring and significant clinical benefit in women with advanced ovarian cancer, regardless of their tumor genetics,” Jonathan A. Ledermann, MD, principal investigator for the ARIEL3 study in Europe and other countries outside the U.S., who presented the data, said in a press release. Ledermann, who is also a professor of medical oncology, and director of Cancer Research UK and UCL Cancer Trials Centre at the University College London Cancer Institute, also spoke of the drug’s ability to enhance the response to earlier chemotherapy. “It is also clinically significant that rucaparib not only sustained patients’ most recent response to platinum, but in some trial participants also enhanced that response, including the radiological elimination of residual tumor,” he said. The Phase 3 ARIEL3 trial (NCT01968213) included people who had responded to treatment with platinum chemotherapy. Patients were recruited into two group
Subscribe or to access all post and page content.